statistiche ricercatore

Nazione	#
IT - Italia	18.815
US - Stati Uniti d'America	820
CN - Cina	135
SG - Singapore	128
DE - Germania	66
VN - Vietnam	58
SE - Svezia	54
UA - Ucraina	40
BR - Brasile	39
GB - Regno Unito	26
FI - Finlandia	19
FR - Francia	17
HK - Hong Kong	10
IN - India	9
CA - Canada	8
ZA - Sudafrica	8
BE - Belgio	7
CO - Colombia	6
IQ - Iraq	6
AR - Argentina	5
BD - Bangladesh	5
ID - Indonesia	5
KR - Corea	5
MX - Messico	5
AU - Australia	4
PL - Polonia	4
RO - Romania	4
AT - Austria	3
NL - Olanda	3
PK - Pakistan	3
TH - Thailandia	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
DZ - Algeria	2
IL - Israele	2
JM - Giamaica	2
JO - Giordania	2
MA - Marocco	2
MY - Malesia	2
PY - Paraguay	2
RS - Serbia	2
RU - Federazione Russa	2
SA - Arabia Saudita	2
TR - Turchia	2
AL - Albania	1
CH - Svizzera	1
DK - Danimarca	1
EC - Ecuador	1
EG - Egitto	1
ES - Italia	1
GE - Georgia	1
IR - Iran	1
JP - Giappone	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
LY - Libia	1
MK - Macedonia	1
MT - Malta	1
NG - Nigeria	1
NO - Norvegia	1
PE - Perù	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
TW - Taiwan	1
Totale	20.367

Nome	#
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis	4.562
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ?	3.141
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis	2.826
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis	2.546
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI	2.431
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ?	2.299
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience	2.017
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution	483
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study	115
Totale	20.420

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	927	0	0	0	0	0	0	0	0	0	376	382	169
2021/2022	857	131	61	28	83	83	40	24	37	120	91	99	60
2022/2023	1.055	70	189	189	73	100	92	42	84	57	62	58	39
2023/2024	1.132	55	124	55	101	88	175	142	78	64	68	98	84
2024/2025	1.330	162	248	229	217	110	119	136	12	24	21	31	21
2025/2026	658	64	49	56	48	60	71	141	45	46	78	0	0
Totale													20.420

UNICA IRIS Institutional Research Information System